SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
The authors screened 19,763 positive COVID-19 individuals at Mount Sinai Health System (NYC, NY) for IgG antibody responses. The study population included patients diagnosed with mild to moderate COVID-19 symptoms and hospital staff voluntarily opting into the study, from March to July 2020.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
Introduction for Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
Antibody Testing in Germany
Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan–implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
Diagnostic Tool for Coronavirus Being Developed by University of Warwick
Saliva could be an alternative fluid to test COVID-19 antibodies
Seroprevalence of anti-SARS-CoV-2 spike protein antibodies in the New York Metropolitan Area
Learn After
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months: Methods
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months: Results
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months: Discussion